Takeda honoured for contributions to Vietnam's sustainable development

At a conference themed “Taking the Lead in Dual Transition for a Greener Vietnam” hosted by Vietnam Investment Review on November 12, Takeda was honoured with the title “In Partnership With Vietnam’s Sustainable Development” for its contributions to the country’s sustainable development goals.

Pham Thi Thu Ha, head of external affairs and communications at Takeda Vietnam, represented the company to receive VIR's trophy for its contribution to Vietnam’s sustainable development. Photo: Duc Thanh

As a biopharmaceutical company with a strong focus on research and development, Takeda has been at the forefront of delivering groundbreaking treatments in Vietnam over the past decade.

Takeda focuses on improving people's lives by researching, developing, and bringing to market innovative medicines and vaccines that are accessible to all, regardless of where they live or their financial means. The company has played a pivotal role in expanding access to life-saving medicines and driving public-private collaborations, all aimed at fostering a more sustainable and resilient healthcare system for the future.

This year, Takeda has made significant strides in the healthcare sector in Vietnam.

In February, Takeda signed an MoU on rare diseases with the Medical Services Administration under the Ministry of Health, in collaboration with Roche, Novartis, and Sanofi. The agreement aims to enhance the diagnosis and treatment of rare diseases, provide continuous education programmes for healthcare professionals, and develop policies to ensure the supply and accessibility of rare disease treatments.

In May, Takeda’s dengue vaccine was approved by the Ministry of Health and is now available at hospitals, clinics, and vaccination centres across the country. The vaccine is a vital component in Vietnam’s comprehensive strategy to manage and control dengue fever.

Since June, Takeda has partnered with the National Institute of Haematology and Blood Transfusion to strengthen expertise in haematology and oncology. This partnership has focused on sharing knowledge related to the treatment of haemophilia, as outlined by Ministry of Health guidelines, and raising awareness about blood cancers, such as lymphoma and multiple myeloma.

Takeda’s continuous efforts demonstrate its commitment to driving sustainable development in Vietnam’s healthcare sector, in alignment with the country’s vision for a healthier future.

Takeda’s decade of healthcare commitments in Vietnam For over 10 years, Takeda has been a dedicated healthcare partner in Vietnam, delivering transformative treatments and contributing significant value to public health. The recent approval of its dengue vaccine further strengthens this commitment. Dion Warren, Takeda’s area head for India and Southeast Asia, talked to VIR’s Bich Thuy about the company’s journey and its plans to bring more innovative medicines to Vietnam.

Takeda's commitment to health equity and access for rare disease community This year's Rare Disease Day, February 29, served as a momentous occasion to celebrate the extraordinary journeys of rare disease patients and their devoted caregivers. Having established a strong presence in the Vietnamese market over many years, Takeda holds steadfast in its commitment to bolstering the wellbeing of the Vietnamese people, especially those afflicted by rare diseases. Than Trong Son, head of Medical Affairs, Takeda Vietnam, delves into Takeda's tireless endeavours and commitment to supporting patients afflicted by rare diseases in the country.

Experts discuss dengue fever prevention in Vietnam Takeda, a global biopharmaceutical company, hosted a series of meetings in Ho Chi Minh City and Hanoi on September 26-27 to discuss the essential role of vaccines in an integrated dengue prevention strategy in Vietnam and globally.